We provide you with 20 years of free, institutional-grade data for ARTL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ARTL. Explore the full financial landscape of ARTL stock.
| Reported Date | CIK | Ticker | Type |
|---|
Artelo Biosciences, Inc(NASDAQ:ARTL) 
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for ...
Website: https://artelobio.com/
Founded: 2011
CEO: Gregory Gorgas
Sector: Manufacturing
Industry: Tobacco Manufacturing
Share this website to your friends
The information provided in this report about ARTL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.